CpG-ODN(K3) / Osaka University Graduate School of Medicine - LARVOL DELTA

First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3). (PubMed, Vaccine) - "BK-SE36/CpG has an acceptable safety profile. Use of CpG-ODN(K3) greatly enhanced immunogenicity in malaria naïve Japanese adults when compared to BK-SE36 alone. The utility of BK-SE36/CpG is currently under evaluation in a malaria endemic setting in West Africa."

Clinical • Journal • P1 data • Immunology • Infectious Disease • Malaria